
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5862200/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Italian Dementia-Friendly Hospital Trial (IDENTITÀ): efficacy of a dementia care intervention for hospital staff. Aging and Mental Health, 2023, 27, 921-929.	2.8	1
2	Ribosomes as a nexus between translation and cancer progression: Focus on ribosomal Receptor for Activated C Kinase 1 (RACK1) in breast cancer. British Journal of Pharmacology, 2022, 179, 2813-2828.	5.4	17
3	Dementia-friendly intervention for hospitalized older adults with cognitive impairments: results of the Italian Dementia-Friendly Hospital Trial (IDENTITÀ). Aging and Mental Health, 2022, 26, 716-724.	2.8	7
4	Nonâ€drug pain relievers active on nonâ€opioid pain mechanisms. Pain Practice, 2022, 22, 255-275.	1.9	15
5	Non-drug interventions in glaucoma: Putative roles for lifestyle, diet and nutritional supplements. Survey of Ophthalmology, 2022, 67, 675-696.	4.0	11
6	Molecular regulations of circadian rhythm and implications for physiology and diseases. Signal Transduction and Targeted Therapy, 2022, 7, 41.	17.1	88
7	The Frailty Puzzle: Searching for Immortality or for Knowledge Survival?. Frontiers in Cellular Neuroscience, 2022, 16, 838447.	3.7	3
8	Nature-Inspired Hybrids (NIH) Improve Proteostasis by Activating Nrf2-Mediated Protective Pathways in Retinal Pigment Epithelial Cells. Antioxidants, 2022, 11, 1385.	5.1	6
9	Cancer and Alzheimer's disease inverse relationship: an age-associated diverging derailment of shared pathways. Molecular Psychiatry, 2021, 26, 280-295.	7.9	68
10	The Peptidyl-prolyl Isomerase Pin1 in Neuronal Signaling: from Neurodevelopment to Neurodegeneration. Molecular Neurobiology, 2021, 58, 1062-1073.	4.0	15
11	(Dys)regulation of Synaptic Activity and Neurotransmitter Release by β-Amyloid: A Look Beyond Alzheimer's Disease Pathogenesis. Frontiers in Molecular Neuroscience, 2021, 14, 635880.	2.9	15
12	Short-and Long-Term Expression of Vegf: A Temporal Regulation of a Key Factor in Diabetic Retinopathy. Frontiers in Pharmacology, 2021, 12, 707909.	3.5	12
13	Medical Devices Made of Substances: Possible Innovation and Opportunities for Complex Natural Products. Planta Medica, 2021, 87, 1110-1116.	1.3	6
14	Pin1 as Molecular Switch in Vascular Endothelium: Notes on Its Putative Role in Age-Associated Vascular Diseases. Cells, 2021, 10, 3287.	4.1	3
15	Targeting dementias through cancer kinases inhibition. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12044.	3.7	15
16	Brain-Heart Communication. , 2020, , 25-41.		2
17	Targeting Cytokine Release Through the Differential Modulation of Nrf2 and NF-ήB Pathways by Electrophilic/Non-Electrophilic Compounds. Frontiers in Pharmacology, 2020, 11, 1256.	3.5	11
18	Drug prescription in elderly hospitalized patients with cognitive impairment in the Italian dementiaâ€friendly hospital project. Alzheimer's and Dementia, 2020, 16, e047619.	0.8	0

#	Article	IF	CITATIONS
19	OXER1 and RACK1-associated pathway: a promising drug target for breast cancer progression. Oncogenesis, 2020, 9, 105.	4.9	25
20	Targeting the microbiota in pharmacology of psychiatric disorders. Pharmacological Research, 2020, 157, 104856.	7.1	35
21	Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2. Signal Transduction and Targeted Therapy, 2020, 5, 84.	17.1	486
22	Eye-Light on Age-Related Macular Degeneration: Targeting Nrf2-Pathway as a Novel Therapeutic Strategy for Retinal Pigment Epithelium. Frontiers in Pharmacology, 2020, 11, 844.	3.5	19
23	Unraveling a new player in multiple sclerosis pathogenesis: The RNA-binding protein HuR. Multiple Sclerosis and Related Disorders, 2020, 41, 102048.	2.0	10
24	Use of dual-flow bioreactor to develop a simplified model of nervous-cardiovascular systems crosstalk: A preliminary assessment. PLoS ONE, 2020, 15, e0242627.	2.5	8
25	Psychiatric and Neurological Effects of Cardiovascular Drugs. , 2020, , 731-744.		Ο
26	Title is missing!. , 2020, 15, e0242627.		0
27	Title is missing!. , 2020, 15, e0242627.		Ο
28	Title is missing!. , 2020, 15, e0242627.		0
29	Title is missing!. , 2020, 15, e0242627.		0
30	Title is missing!. , 2020, 15, e0242627.		0
31	Title is missing!. , 2020, 15, e0242627.		0
32	Systematic Review and Metaâ€Analysis on Neuropsychological Effects of Longâ€Term Use of Opioids in Patients With Chronic Noncancer Pain. Pain Practice, 2019, 19, 328-343.	1.9	32
33	Amyloid-β and Synaptic Vesicle Dynamics: A Cacophonic Orchestra. Journal of Alzheimer's Disease, 2019, 72, 1-14.	2.6	24
34	The role of gut microbiota in obesity, diabetes mellitus, and effect of metformin: new insights into old diseases. Current Opinion in Pharmacology, 2019, 49, 1-5.	3.5	188
35	Beta-amyloid short- and long-term synaptic entanglement. Pharmacological Research, 2019, 139, 243-260.	7.1	21
36	Modulation of Keap1/Nrf2/ARE Signaling Pathway by Curcuma- and Garlic-Derived Hybrids. Frontiers in Pharmacology, 2019, 10, 1597.	3.5	53

#	Article	IF	CITATIONS
37	Brain-Heart Communication. , 2019, , 1-17.		1
38	Microbiota and metabolic diseases. Endocrine, 2018, 61, 357-371.	2.3	280
39	Experimental Paradigm for the Assessment of the Non-pharmacological Mechanism of Action in Medical Device Classification: The Example of Clycerine as Laxative. Frontiers in Pharmacology, 2018, 9, 1410.	3.5	5
40	The Role of Endogenous Neuroprotective Mechanisms in the Prevention of Retinal Ganglion Cells Degeneration. Frontiers in Neuroscience, 2018, 12, 834.	2.8	56
41	Autophagy Stimulus Promotes Early HuR Protein Activation and p62/SQSTM1 Protein Synthesis in ARPE-19 Cells by Triggering Erk1/2, p38 <sup>MAPK</sup> , and JNK Kinase Pathways. Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-15.	4.0	26
42	Drug prescription appropriateness in the elderly: an Italian study. Clinical Interventions in Aging, 2017, Volume 12, 325-333.	2.9	10
43	Protein Kinase C Signal Transmission During Aging. , 2017, , 269-292.		0
44	Abstinence from cocaineâ€selfâ€administration activates the nELAV/GA <i>P</i> â€43 pathway in the hippocampus: A stressâ€related effect?. Hippocampus, 2016, 26, 700-704.	1.9	0
45	PKC Activation Counteracts ADAM10 Deficit in HuD-Silenced Neuroblastoma Cells. Journal of Alzheimer's Disease, 2016, 54, 535-547.	2.6	10
46	Nanosystems based on siRNA silencing HuR expression counteract diabetic retinopathy in rat. Pharmacological Research, 2016, 111, 713-720.	7.1	84
47	Insights into the definition of terms in European medical device regulation. Expert Review of Medical Devices, 2016, 13, 907-917.	2.8	21
48	Targeting VEGF in eye neovascularization: What's new?. Pharmacological Research, 2016, 103, 253-269.	7.1	137
49	Human Genetic Variability Contributes to Postoperative Morphine Consumption. Journal of Pain, 2016, 17, 628-636.	1.4	57
50	Cerebral Aging: Implications for the Heart Autonomic Nervous System Regulation. , 2016, , 115-127.		4
51	Preâ€exposure of neuroblastoma cell line to pulsed electromagnetic field prevents H <sub>2</sub> O <sub>2</sub> â€induced ROS production by increasing MnSOD activity. Bioelectromagnetics, 2015, 36, 219-232.	1.6	44
52	Defective DNA repair and increased chromatin binding of DNA repair factors in Down syndrome fibroblasts. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2015, 780, 15-23.	1.0	12
53	Serotonin transporter polymorphism modifies the association between depressive symptoms and sleep onset latency complaint in elderly people: results from the â€~InveCe.Ab' study. Journal of Sleep Research, 2015, 24, 215-222.	3.2	10
54	Induction of <i>VEGFA</i> mRNA translation by CoCl <sub>2</sub> mediated by HuR. RNA Biology, 2015, 12, 1121-1130.	3.1	30

#	Article	IF	CITATIONS
55	Effects of soluble β-amyloid on the release of neurotransmitters from rat brain synaptosomes. Frontiers in Aging Neuroscience, 2014, 6, 166.	3.4	19
56	Autophagy Is Modulated in Human Neuroblastoma Cells Through Direct Exposition to Low Frequency Electromagnetic Fields. Journal of Cellular Physiology, 2014, 229, 1776-1786.	4.1	51
57	Clinical Pharmacokinetics of Morphine and Its Metabolites During Morphine Dose Titration for Chronic Cancer Pain. Therapeutic Drug Monitoring, 2014, 36, 335-344.	2.0	19
58	Novel approaches to the post-myocardial infarction/heart failure neural remodeling. Heart Failure Reviews, 2014, 19, 611-619.	3.9	15
59	Inhibitory effects of beta-amyloid on the nicotinic receptors which stimulate glutamate release in rat hippocampus: the glial contribution. European Journal of Pharmacology, 2014, 723, 314-321.	3.5	11
60	Are Hsp70 protein expression and genetic polymorphism implicated in multiple sclerosis inflammation?. Journal of Neuroimmunology, 2014, 268, 84-88.	2.3	23
61	Involvement of ELAV RNA-binding proteins in the post-transcriptional regulation of HO-1. Frontiers in Cellular Neuroscience, 2014, 8, 459.	3.7	14
62	Dangerous Liaisons between Beta-Amyloid and Cholinergic Neurotransmission. Current Pharmaceutical Design, 2014, 20, 2525-2538.	1.9	18
63	Pharmacological modulation of the state of awareness in patients with disorders of consciousness: an overview. Current Pharmaceutical Design, 2014, 20, 4121-39.	1.9	16
64	Genetic variability at COMT but not at OPRM1 and UGT2B7 loci modulates morphine analgesic response in acute postoperative pain. European Journal of Clinical Pharmacology, 2013, 69, 1651-1658.	1.9	62
65	Posttranscriptional regulation of SOD1 gene expression under oxidative stress: Potential role of ELAV proteins in sporadic ALS. Neurobiology of Disease, 2013, 60, 51-60.	4.4	40
66	ldentification of Peptides with <scp>ELAV</scp> â€like <scp>mRNA</scp> â€Gtabilizing Effect: An Integrated <i>In Vitro</i> / <i>In Silico</i> Approach. Chemical Biology and Drug Design, 2013, 81, 707-714.	3.2	8
67	Zyxin is a novel target for betaâ€amyloid peptide: characterization of its role in Alzheimer's pathogenesis. Journal of Neurochemistry, 2013, 125, 790-799.	3.9	20
68	The C1 domain-targeted isophthalate derivative HMI-1b11 promotes neurite outgrowth and GAP-43 expression through PKCα activation in SH-SY5Y cells. Pharmacological Research, 2013, 73, 44-54.	7.1	28
69	Do we need pharmacogenetics to personalize antidepressant therapy?. Cellular and Molecular Life Sciences, 2013, 70, 3327-3340.	5.4	6
70	Conformational altered p53 affects neuronal function: relevance for the response to toxic insult and growth-associated protein 43 expression. Cell Death and Disease, 2013, 4, e484-e484.	6.3	30
71	Autophagy Activation Clears ELAVL1/HuR-Mediated Accumulation of SQSTM1/p62 during Proteasomal Inhibition in Human Retinal Pigment Epithelial Cells. PLoS ONE, 2013, 8, e69563.	2.5	138
72	Consequences of the 118A>G polymorphism in the OPRM1 gene: translation from bench to bedside?. Journal of Pain Research, 2013, 6, 331.	2.0	79

#	Article	IF	CITATIONS
73	Pharmacological modulation of the state of awareness in patients with Disorders of Consciousness: an Overview. Current Pharmaceutical Design, 2013, 999, 5-6.	1.9	16
74	Modulation of Rack-1/PKCβII Signalling By Soluble AβPPα in SH-SY5Y Cells. Current Alzheimer Research, 2013, 10, 697-705.	1.4	18
75	Influence of COMT Val158Met Polymorphism on Alzheimer's Disease and Mild Cognitive Impairment in Italian Patients. Journal of Alzheimer's Disease, 2012, 32, 919-926.	2.6	30
76	Pentraxins and Alzheimer's disease: At the interface between biomarkers and pharmacological targets. Ageing Research Reviews, 2012, 11, 189-198.	10.9	21
77	Protecting the retinal neurons from glaucoma: Lowering ocular pressure is not enough. Pharmacological Research, 2012, 66, 19-32.	7.1	45
78	Dual Effect of Beta-Amyloid on α7 and α4β2 Nicotinic Receptors Controlling the Release of Glutamate, Aspartate and GABA in Rat Hippocampus. PLoS ONE, 2012, 7, e29661.	2.5	59
79	Conformational Altered p53 as an Early Marker of Oxidative Stress in Alzheimer's Disease. PLoS ONE, 2012, 7, e29789.	2.5	59
80	Beta Amyloid Differently Modulate Nicotinic and Muscarinic Receptor Subtypes which Stimulate in vitro and in vivo the Release of Glycine in the Rat Hippocampus. Frontiers in Pharmacology, 2012, 3, 146.	3.5	16
81	p53 at the crossroads between cancer and neurodegeneration. Free Radical Biology and Medicine, 2012, 52, 1727-1733.	2.9	84
82	The complex world of post-transcriptional mechanisms: is their deregulation a common link for diseases? Focus on ELAV-like RNA-binding proteins. Cellular and Molecular Life Sciences, 2012, 69, 501-517.	5.4	75
83	AβPP Intracellular C-Terminal Domain Function is Related to its Degradation Processes. Journal of Alzheimer's Disease, 2012, 30, 393-405.	2.6	14
84	Cytoprotective Response Induced by Electromagnetic Stimulation on SH-SY5Y Human Neuroblastoma Cell Line. Tissue Engineering - Part A, 2011, 17, 2573-2582.	3.1	34
85	NGF and heart: Is there a role in heart disease?. Pharmacological Research, 2011, 63, 266-277.	7.1	50
86	001. A narrative review on assessment of pain in dementia patients. European Journal of Pain Supplements, 2011, 5, 507-507.	0.0	0
87	Different presynaptic nicotinic receptor subtypes modulate in vivo and in vitro the release of glycine in the rat hippocampus. Neurochemistry International, 2011, 59, 729-738.	3.8	11
88	Localization of dopamine receptors in the rat cerebral cortex. Journal of Pharmacy and Pharmacology, 2011, 28, 244-245.	2.4	21
89	Effect of ergotamine and dihydroergotamine on dopamine-stimulated adenylate cyclase in rat caudate nucleus. Journal of Pharmacy and Pharmacology, 2011, 29, 45-47.	2.4	7
90	Differential effects of caffeine on dihydroxyphenylacetic acid concentrations in various rat brain dopaminergic structures. Journal of Pharmacy and Pharmacology, 2011, 36, 458-460.	2.4	24

#	Article	IF	CITATIONS
91	ELAV–GAP43 pathway activation following combined exposure to cocaine and stress. Psychopharmacology, 2011, 218, 249-256.	3.1	8
92	The Expanding Universe of Neurotrophic Factors: Therapeutic Potential in Aging and Age-Associated Disorders. Current Pharmaceutical Design, 2010, 16, 698-717.	1.9	46
93	β -Amyloid: A Disease Target or a Synaptic Regulator Affecting Age-Related Neurotransmitter Changes?. Current Pharmaceutical Design, 2010, 16, 672-683.	1.9	30
94	How and Why to Screen for CYP2D6 Interindividual Variability in Patients Under Pharmacological Treatments. Current Drug Metabolism, 2010, 11, 276-282.	1.2	39
95	Senescence of the Brain: Focus on Cognitive Kinases. Current Pharmaceutical Design, 2010, 16, 660-671.	1.9	48
96	Unfolded p53 in Blood as a Predictive Signature Signature of the Transition from Mild Cognitive Impairment to Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 20, 97-104.	2.6	31
97	Recruitment of Casein Kinase 2 is Involved in AβPP Processing Following Cholinergic Stimulation. Journal of Alzheimer's Disease, 2010, 20, 1133-1141.	2.6	7
98	Wild type but not mutant APP is involved in protective adaptive responses against oxidants. Amino Acids, 2010, 39, 271-283.	2.7	11
99	The PKCβ/HuR/VEGF pathway in diabetic retinopathy. Biochemical Pharmacology, 2010, 80, 1230-1237.	4.4	95
100	Soluble βamyloid <sub>1â€42</sub> : a critical player in producing behavioural and biochemical changes evoking depressiveâ€related state?. British Journal of Pharmacology, 2010, 159, 1704-1715.	5.4	95
101	Phosphorylation of APPâ€CTFâ€AICD domains and interaction with adaptor proteins: signal transduction and/or transcriptional role – relevance for Alzheimer pathology. Journal of Neurochemistry, 2010, 115, 1299-1308.	3.9	60
102	Drug-DNA interaction protocols. European Journal of Histochemistry, 2010, 54, .	1.5	0
103	Homeodomain Interacting Protein Kinase 2: A Target for Alzheimer's Beta Amyloid Leading to Misfolded p53 and Inappropriate Cell Survival. PLoS ONE, 2010, 5, e10171.	2.5	50
104	Specific Neuromodulatory Actions of Amyloid-β on Dopamine Release in Rat Nucleus Accumbens and Caudate Putamen. Journal of Alzheimer's Disease, 2010, 19, 1041-1053.	2.6	20
105	Awakenings and Awareness Recovery in Disorders of Consciousness. CNS Drugs, 2010, 24, 625-638.	5.9	54
106	Individualizing pain therapy with opioids: The rational approach based on pharmacogenetics and pharmacokinetics. European Journal of Pain Supplements, 2010, 4, 245-250.	0.0	7
107	β-Amyloid precursor protein metabolism: focus on the functions and degradation of its intracellular domain. Pharmacological Research, 2010, 62, 308-317.	7.1	62
108	Specific inhibitory effect of amyloid-β on presynaptic muscarinic receptor subtypes modulating neurotransmitter release in the rat nucleus accumbens. Neuroscience, 2010, 167, 482-489.	2.3	17

#	Article	IF	CITATIONS
109	Unfolded p53 in the pathogenesis of Alzheimer's disease: is HIPK2 the link?. Aging, 2010, 2, 545-554.	3.1	44
110	Monoamines. , 2009, , 931-937.		0
111	Depression and antidepressants: molecular and cellular aspects. Cellular and Molecular Life Sciences, 2009, 66, 2985-3008.	5.4	70
112	Why do centenarians escape or postpone cancer? The role of IGF-1, inflammation and p53. Cancer Immunology, Immunotherapy, 2009, 58, 1909-1917.	4.2	79
113	Discovery of Small Peptides Derived from Embryonic Lethal Abnormal Vision Proteins Structure Showing RNA-Stabilizing Properties. Journal of Medicinal Chemistry, 2009, 52, 5017-5019.	6.4	19
114	"Functional mapping of the promoter region of the GNB2L1 human gene coding for RACK1 scaffold protein― Gene, 2009, 430, 17-29.	2.2	28
115	Intrathecal Baclofen in Patients With Persistent Vegetative State: 2 Hypotheses. Archives of Physical Medicine and Rehabilitation, 2009, 90, 1245-1249.	0.9	66
116	Interindividual variability of drug transporters: Impact on opioid treatment in chronic renal failure. European Journal of Pain Supplements, 2009, 3, 21-28.	0.0	2
117	Alzheimer's disease: new diagnostic and therapeutic tools. Immunity and Ageing, 2008, 5, 7.	4.2	22
118	Conformationally altered p53: a novel Alzheimer's disease marker?. Molecular Psychiatry, 2008, 13, 641-647.	7.9	73
119	PKCβII/HuR/VEGF: A new molecular cascade in retinal pericytes for the regulation of VEGF gene expression. Pharmacological Research, 2008, 57, 60-66.	7.1	46
120	Cognition enhancers between treating and doping the mind. Pharmacological Research, 2008, 57, 196-213.	7.1	114
121	Conformationally Altered p53: A Putative Peripheral Marker for Alzheimer's Disease. Neurodegenerative Diseases, 2008, 5, 209-211.	1.4	32
122	Pain and the pharmacogenetics at the fuzzy border between pain physiopathology and pain treatment. European Journal of Pain Supplements, 2008, 2, 5-12.	0.0	2
123	Acute β-Amyloid Administration Disrupts the Cholinergic Control of Dopamine Release in the Nucleus Accumbens. Neuropsychopharmacology, 2008, 33, 1062-1070.	5.4	47
124	Post-Transcriptional Regulation of HSP70 Expression Following Oxidative Stress in SH-SY5Y Cells: The Potential Involvement of the RNA-Binding Protein HuR. Current Pharmaceutical Design, 2008, 14, 2651-2658.	1.9	59
125	Pharmacogenetics and Pharmagenomics, Trends in Normal and Pathological Aging Studies: Focus on p53. Current Pharmaceutical Design, 2008, 14, 2665-2671.	1.9	23
126	Role of b-Amyloid in the Pathophysiology of Alzheimer's Disease and Cholinesterase Inhibition: Facing the Biological Complexity to Treat the Disease. , 2008, , 439-444.		0

#	Article	IF	CITATIONS
127	Unfolded p53: A Potential Biomarker for Alzheimer's Disease. Journal of Alzheimer's Disease, 2007, 12, 93-99.	2.6	48
128	Soluble amyloid beta1-42 reduces dopamine levels in rat prefrontal cortex: Relationship to nitric oxide. Neuroscience, 2007, 147, 652-663.	2.3	37
129	The aging brain, a key target for the future: The protein kinase C involvement. Pharmacological Research, 2007, 55, 560-569.	7.1	84
130	Selective impairment of noradrenergic transmission in the bisected rat vas deferens following photochemically-induced cerebral ischaemia. Journal of Developmental and Physical Disabilities, 2007, 30, 129-136.	3.6	3
131	Overâ€expression of amyloid precursor protein in HEK cells alters p53 conformational state and protects against doxorubicin. Journal of Neurochemistry, 2007, 103, 322-333.	3.9	27
132	Nicotinic component of galantamine in the regulation of amyloid precursor protein processing. Chemico-Biological Interactions, 2007, 165, 138-145.	4.0	19
133	RACK-1 expression and cytokine production in leukocytes obtained from AD patients. Aging Clinical and Experimental Research, 2006, 18, 153-157.	2.9	12
134	Role of acetylcholinesterase inhibitors in pharmacological regulation of amyloid precursor protein processing. Aging Clinical and Experimental Research, 2006, 18, 149-152.	2.9	8
135	Sex after stroke: A CNS only dysfunction?. Pharmacological Research, 2006, 54, 11-18.	7.1	27
136	Identification of a mutant-like conformation of p53 in fibroblasts from sporadic Alzheimer's disease patients. Neurobiology of Aging, 2006, 27, 1193-1201.	3.1	57
137	The search for disease-modifying drugs for neurodegenerative disorders. Future Neurology, 2006, 1, 87-96.	0.5	Ο
138	Effects of hormone therapy on brain morphology of healthy postmenopausal women. Menopause, 2006, 13, 584-591.	2.0	81
139	Estrogen receptor <i>α</i> and APOE <i>É&gt;</i> 4 polymorphisms interact to increase risk for sporadic AD in Italian females. European Journal of Neurology, 2006, 13, 639-644.	3.3	44
140	High interleukin-10 production is associated with low antibody response to influenza vaccination in the elderly. Journal of Leukocyte Biology, 2006, 80, 376-382.	3.3	51
141	Role of acetylcholinesterase inhibitors in the regulation of amyloid β precursor protein (AβPP) metabolism. Chemico-Biological Interactions, 2005, 157-158, 335-338.	4.0	16
142	Age-related decline in RACK-1 expression in human leukocytes is correlated to plasma levels of dehydroepiandrosterone. Journal of Leukocyte Biology, 2005, 77, 247-256.	3.3	31
143	Neuronal ELAV proteins enhance mRNA stability by a PKCÂ-dependent pathway. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 12065-12070.	7.1	132
144	Increase of the RNA-binding protein HuD and posttranscriptional up-regulation of the GAP-43 gene during spatial memory. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 1217-1222.	7.1	169

#	Article	IF	CITATIONS
145	Differential involvement of protein kinase C alpha and epsilon in the regulated secretion of soluble amyloid precursor protein. FEBS Journal, 2004, 271, 3068-3075.	0.2	48
146	Familial Migraine With Aura: Association Study With 5-HT1B/1D, 5-HT2C, and hSERT Polymorphisms. Headache, 2004, 44, 311-317.	3.9	29
147	Capillary electrophoresis studies on the aggregation process ofβ-amyloid 1-42 and 1-40 peptides. Electrophoresis, 2004, 25, 3186-3194.	2.4	73
148	In Vitro and ex Vivo Antihydroxyl Radical Activity of Green and Roasted Coffee. Journal of Agricultural and Food Chemistry, 2004, 52, 1700-1704.	5.2	92
149	Acetylcholinesterase inhibitors: novel activities of old molecules. Pharmacological Research, 2004, 50, 441-451.	7.1	253
150	Emerging targets for the pharmacology of learning and memory. Pharmacological Research, 2004, 50, 111-122.	7.1	26
151	Alzheimer?s disease: facing the biological complexity to treat the disease. Pharmacological Research, 2004, 50, 381-383.	7.1	0
152	Expression and phosphorylation of δ-CaM kinase II in cultured Alzheimer fibroblasts. Neurobiology of Aging, 2004, 25, 1187-1196.	3.1	7
153	Characterization of the effect of ganstigmine (CHF2819) on amyloid precursor protein metabolism in SH-SY5Y neuroblastoma cells. Journal of Neural Transmission, 2003, 110, 935-947.	2.8	26
154	The pharmacology of amyloid precursor protein processing. Experimental Gerontology, 2003, 38, 145-157.	2.8	50
155	Role of protein kinase Cα in the regulated secretion of the amyloid precursor protein. Molecular Psychiatry, 2003, 8, 209-216.	7.9	42
156	In Vivo Dehydroepiandrosterone Restores Age-Associated Defects in the Protein Kinase C Signal Transduction Pathway and Related Functional Responses. Journal of Immunology, 2002, 168, 1753-1758.	0.8	54
157	Antiradical Activity of Water Soluble Components in Common Diet Vegetables. Journal of Agricultural and Food Chemistry, 2002, 50, 1272-1277.	5.2	32
158	Ischemia-induced glutamate release in rat frontoparietal cortex after chronic alcohol and withdrawal. Neuroscience Letters, 2002, 326, 183-186.	2.1	12
159	Activity of α-Secretase as the Common Final Effector of Protein Kinase C-Dependent and -Independent Modulation of Amyloid Precursor Protein Metabolism. Journal of Neurochemistry, 2002, 72, 2464-2470.	3.9	32
160	Acute cerebral focal ischaemia alters the adrenergic and NANC responses in the bisected rat vas deferens. British Journal of Pharmacology, 2002, 135, 1723-1732.	5.4	4
161	Selective impairment of p53-mediated cell death in fibroblasts from sporadic Alzheimer's disease patients. Journal of Cell Science, 2002, 115, 3131-3138.	2.0	70
162	Selective impairment of p53-mediated cell death in fibroblasts from sporadic Alzheimer's disease patients. Journal of Cell Science, 2002, 115, 3131-8.	2.0	55

#	Article	IF	CITATIONS
163	The Cycloxygenase-2 inhibitor SC58236 is neuroprotective in an in vivo model of focal ischemia in the rat. Neuroscience Letters, 2001, 303, 91-94.	2.1	69
164	Dehydroepiandrosterone and the relationship with aging and memory: a possible link with protein kinase C functional machinery. Brain Research Reviews, 2001, 37, 287-293.	9.0	45
165	β amyloid-induced disruption of ionic balance: studies on the isolated frog labyrinth. NeuroReport, 2001, 12, 2493-2497.	1.2	2
166	Effect of in vivo and in vitro ethanol on adrenergic and purinergic responses of the bisected rat vas deferens to low and high frequency pulses. Autonomic and Autacoid Pharmacology, 2001, 21, 171-179.	0.6	6
167	Bladder instability: a re-appraisal of classical experimental approaches and development of new therapeutic strategies. Autonomic and Autacoid Pharmacology, 2001, 21, 219-229.	0.6	22
168	Extrapyramidal symptoms and antidepressant drugs: neuropharmacological aspects of a frequent interaction in the elderly. Molecular Psychiatry, 2001, 6, 134-142.	7.9	56
169	Short- and long-term effect of acetylcholinesterase inhibition on the expression and metabolism of the amyloid precursor protein. Molecular Psychiatry, 2001, 6, 520-528.	7.9	53
170	Alcohol differentially affects noradrenergic and purinergic responses in the bisected rat vas deferens. Alcohol, 2000, 22, 91-96.	1.7	13
171	Effect of acute alcohol on ischemia-induced glutamate release and brain damage. Alcohol, 2000, 22, 173-177.	1.7	5
172	Influence of different anaesthetics on extracellular aminoacids in rat brain. Journal of Neuroscience Methods, 2000, 101, 165-169.	2.5	35
173	Wild-Type Huntingtin Protects from Apoptosis Upstream of Caspase-3. Journal of Neuroscience, 2000, 20, 3705-3713.	3.6	349
174	Insulin regulates soluble amyloid precursor protein release via phosphatidyl inositol 3 kinaseâ€dependent pathway. FASEB Journal, 2000, 14, 1015-1022.	0.5	161
175	STAT signalling in the mature and aging brain. International Journal of Developmental Neuroscience, 2000, 18, 439-446.	1.6	55
176	Energy metabolism inhibition impairs amyloid precursor protein secretion from Alzheimer's fibroblasts. Neuroscience Letters, 1999, 263, 197-200.	2.1	29
177	Rationalizing a pharmacological intervention on the amyloid precursor protein metabolism. Trends in Pharmacological Sciences, 1999, 20, 418-423.	8.7	49
178	Menopause and estrogen deficiency as a risk factor in dementing illness: hypothesis on the biological basis. Maturitas, 1999, 31, 95-101.	2.4	22
179	Protein Kinase C Anchoring Deficit in Postmortem Brains of Alzheimer's Disease Patients. Experimental Neurology, 1999, 159, 559-564.	4.1	79
180	Association of the Estrogen Receptor α Gene Polymorphisms with Sporadic Alzheimer's Disease. Biochemical and Biophysical Research Communications, 1999, 265, 335-338.	2.1	122

#	Article	IF	CITATIONS
181	Expression of the JAK and STAT superfamilies in human meningiomas. Journal of Neurosurgery, 1999, 91, 440-446.	1.6	41
182	Amyloid precursor protein metabolism in fibroblasts from individuals with one, two or three copies of the amyloid precursor protein (APP) gene. Biochemical Journal, 1999, 338, 777-782.	3.7	10
183	Amyloid precursor protein metabolism in fibroblasts from individuals with one, two or three copies of the amyloid precursor protein (APP) gene. Biochemical Journal, 1999, 338, 777.	3.7	5
184	Dehydroepiandrosterone Sulfate Decreases the Interleukin-2-Mediated Overactivity of the Natural Killer Cell Compartment in Senile Dementia of the Alzheimer Type. Dementia and Geriatric Cognitive Disorders, 1999, 10, 21-27.	1.5	34
185	Role of Estrogens in Dementing Illnesses: Hypotheses on the Biological Rationale. , 1999, , 151-156.		Ο
186	Members of the JAK/STAT proteins are expressed and regulated during development in the mammalian forebrain. , 1998, 54, 320-330.		103
187	Age-related alteration of PKC, a key enzyme in memory processes. Molecular Neurobiology, 1998, 16, 49-62.	4.0	78
188	Effects of Chronic Low-Dose Ethanol Intake on Sexual Behavior in Rats. Alcohol, 1998, 16, 135-138.	1.7	11
189	Increased Natural Killer Cell Cytotoxicity in Alzheimer's Disease May Involve Protein Kinase C Dysregulation. Neurobiology of Aging, 1998, 19, 191-199.	3.1	50
190	Specific role for protein kinase Cα in the constitutive and regulated secretion of amyloid precursor protein in human skin fibroblasts. Neuroscience Letters, 1998, 240, 97-101.	2.1	54
191	The β-oxidation of arachidonic acid and the synthesis of docosahexaenoic acid are selectively and consistently altered in skin fibroblasts from three Zellweger patients versus X-adrenoleukodystrophy, Alzheimer and control subjects. Neuroscience Letters, 1998, 250, 145-148.	2.1	16
192	Fibroblasts from Alzheimer's disease donors do not differ from controls in response to heat shock. Neuroscience Letters, 1998, 256, 25-28.	2.1	3
193	N-[ï‰-(Tetralin-1-yl)alkyl] Derivatives of 3,3-Dimethylpiperidine Are Highly Potent and Selective σ1 or σ2 Ligands. Journal of Medicinal Chemistry, 1998, 41, 3940-3947.	6.4	18
194	Calcium Responses in Fibroblasts from Asymptomatic Members of Alzheimer's Disease Families. Neurobiology of Disease, 1998, 5, 37-45.	4.4	126
195	Moderate Alcohol Intake: Behavioral and Neurochemical Correlates in Rats. Nutritional Neuroscience, 1998, 1, 151-159.	3.1	7
196	Cytosolic hippocampal PKC and aging. NeuroReport, 1998, 9, 725-729.	1.2	20
197	Bradykinin-induced amyloid precursor protein secretion: a protein kinase C-independent mechanism that is not altered in fibroblasts from patients with sporadic Alzheimer's disease. Biochemical Journal, 1998, 330, 1271-1275.	3.7	25
198	Secretory processing of amyloid precursor protein is inhibited by increase in cellular cholesterol content. Biochemical Journal, 1997, 322, 893-896.	3.7	162

#	Article	IF	CITATIONS
199	The role of anchoring protein rack1 in pkc activation in the ageing rat brain. Trends in Neurosciences, 1997, 20, 410-415.	8.6	84
200	Effect of energy shortage and oxidative stress on amyloid precursor protein metabolism in COS cells. Neuroscience Letters, 1997, 231, 113-117.	2.1	88
201	Oxidative metabolism in cultured fibroblasts derived from sporadic Alzheimer's disease (AD) patients. Neuroscience Letters, 1997, 236, 13-16.	2.1	76
202	Expression and activation of SH2/PTB-containing ShcA adaptor protein reflects the pattern of neurogenesis in the mammalian brain. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 8185-8190.	7.1	70
203	Chronic low doses of ethanol affect brain protein kinase C and ultrasonic calls in rats. Alcohol, 1997, 14, 557-561.	1.7	13
204	Estrogen Effect on Brain Biology and Cognition. Medical Science Symposia Series, 1997, , 191-198.	0.0	1
205	New Ïf and 5-HT1AReceptor Ligands: ω-(Tetralin-1-yl)-n-alkylamine Derivatives. Journal of Medicinal Chemistry, 1996, 39, 176-182.	6.4	39
206	Calcium responses in human fibroblasts: A diagnostic molecular profile for Alzheimer's disease. Neurobiology of Aging, 1996, 17, 549-555.	3.1	70
207	Changes in β amyloid precursor protein secretion associated with the proliferative status of CNS derived progenitor cells. Neuroscience Letters, 1996, 212, 199-203.	2.1	16
208	Differential isoform-specific regulation of calcium-independent protein kinase C in rat cerebral cortex. Neuroscience Letters, 1996, 214, 99-102.	2.1	15
209	Peripheral cells as an investigational tool for Alzheimer's disease. Life Sciences, 1996, 59, 461-468.	4.3	22
210	Non-virally mediated gene transfer into human central nervous system precursor cells. Molecular Brain Research, 1996, 42, 161-166.	2.3	16
211	Novel Potent Ïf 1Ligands:ÂN-[ω-(Tetralin-1-yl)alkyl]piperidine Derivatives. Journal of Medicinal Chemistry, 1996, 39, 4255-4260.	6.4	7
212	Lead Contamination in the Mallard ( Anas platyrhynchos ) in Italy. Bulletin of Environmental Contamination and Toxicology, 1996, 56, 729-733.	2.7	11
213	Clinical correlates of apolipoprotein E in Alzheimer's disease. Annals of Neurology, 1996, 40, 688-689.	5.3	2
214	Scattered primary and conditionally immortalized neuroepithelial cells transplanted into the embryonic rat brain differentiate into neurons and glial cells. Neuroscience Research Communications, 1996, 18, 175-183.	0.2	1
215	Activation of the JAK/STAT Pathway Leads to Proliferation of ST14A Central Nervous System Progenitor Cells. Journal of Biological Chemistry, 1996, 271, 23374-23379.	3.4	41
216	Functional Impairment in Protein Kinase C by RACK1 (Receptor for Activated C Kinase 1) Deficiency in Aged Rat Brain Cortex. Journal of Neurochemistry, 1996, 67, 2471-2477.	3.9	77

#	Article	IF	CITATIONS
217	Gene dose of the ε4 allele of apolipoprotein E and disease progression in sporadic lateâ€onset alzheimer's disease. Annals of Neurology, 1995, 37, 596-604.	5.3	153
218	High Affinity and Selectivity on 5-HT1A Receptor of 1-Aryl-4-[(1-tetralin)alkyl]piperazines. 2. Journal of Medicinal Chemistry, 1995, 38, 942-949.	6.4	92
219	Defective phorbol ester-stimulated secretion of β-amyloid precursor protein from Alzheimer's disease fibroblasts. Neuroscience Letters, 1995, 201, 1-4.	2.1	60
220	Protein kinase C activity, translocation, and conventional isoforms in aging rat brain. Neurobiology of Aging, 1995, 16, 137-148.	3.1	78
221	Inositol 1,4,5-trisphosphate receptor and ryanodine receptor in the aging brain of Wistar rats. Neurobiology of Aging, 1994, 15, 203-206.	3.1	33
222	Intracellular Signalling in the Aging Brain Annals of the New York Academy of Sciences, 1994, 719, 271-284.	3.8	13
223	Characterization and Distribution of Protein Kinase C Isoforms in Human Skin Fibroblasts. Archives of Biochemistry and Biophysics, 1994, 314, 107-111.	3.0	31
224	PKC Activity in Rat C6 Glioma Cells: Changes Associated with Cell Cycle and Simvastatin Treatment. Biochemical and Biophysical Research Communications, 1994, 200, 1143-1149.	2.1	26
225	Regulation of Protein Kinase C in NG108-15 Cell Differentiation. Biochemical and Biophysical Research Communications, 1994, 201, 135-142.	2.1	14
226	Expression and Regulation of Calcium Independent Protein Kinase C in NG 108-15 Cell Differentiation. Biochemical and Biophysical Research Communications, 1994, 203, 1423-1431.	2.1	16
227	Mixed 5-HT1A/D-2 activity of a new model of ary piperazines: 1-aryl-4-[3-(1,2-dihydronaphthalen-4-yl)-n-propyl]piperazines. 1. Synthesis and structure-activity relationships. Journal of Medicinal Chemistry, 1994, 37, 99-104.	6.4	38
228	Protein kinase C activation and anti-amnesic effect of acetyl-L-carnitine: in vitro and in vivo studies. European Journal of Pharmacology, 1994, 265, 1-7.	3.5	32
229	Apolipoprotein E ε4 Allele in Alzheimer's Disease and Vascular Dementia. Dementia and Geriatric Cognitive Disorders, 1994, 5, 240-242.	1.5	47
230	Apolipoprotein E epsilon 4 allele frequency in vascular dementia and Alzheimer's disease Stroke, 1994, 25, 1703-1704.	2.0	41
231	Calcium Ion Homeostasis in the Aging Brain: Regulation of Voltage-Dependent Calcium Channels. E&M Endocrinology and Metabolism, 1994, , 418-435.	0.1	0
232	Cognition stimulating drugs modulate protein kinase C activity in cerebral cortex and hippocampus of adult rats. Life Sciences, 1993, 53, 1821-1832.	4.3	32
233	PKC Translocation in Rat Brain Cortex Is Promoted in Vivo and in Vitro by α-Glycerylphosphorylcholine, a Cognition-enhancing Druga. Annals of the New York Academy of Sciences, 1993, 695, 307-310.	3.8	3
234	Effect of Aging on Brain Voltage-Dependent Calcium Channels. Medical Science Symposia Series, 1993, , 231-240.	0.0	1

#	Article	IF	CITATIONS
235	Protein kinase C increase in rat brain cortical membranes may be promoted by cognition enhancing drugs. Life Sciences, 1992, 50, PL125-PL128.	4.3	16
236	Perinatal ethanol exposure and dopaminergic transmission. Pharmacological Research, 1992, 26, 21.	7.1	0
237	Modifications of PKC during aging in different brain areas of wistar male rats. Pharmacological Research, 1992, 26, 129.	7.1	0
238	PKC activity in fibroblasts from Alzheimer's disease donors. Pharmacological Research, 1992, 26, 129.	7.1	0
239	Oxygen isosteric derivatives of 3-(3-hydroxyphenyl)-N-n-propylpiperidine. Journal of Medicinal Chemistry, 1992, 35, 3045-3049.	6.4	15
240	Maitotoxin-Induced Intracellular Calcium Rise in PC 12 Cells: Involvement of Dihydropyridine-Sensitive and ?-Conotoxin-Sensitive Calcium Channels and Phosphoinositide Breakdown. Journal of Neurochemistry, 1992, 59, 679-688.	3.9	26
241	Chronic treatment with an acetylcholine synthesis precursor, alpha-glycerylphosphorylcholine, alters brain parameters linked to cholinergic transmission and passive avoidance behavior. Drug Development Research, 1992, 26, 439-447.	2.9	3
242	The aging brain: Protein phosphorylation as a target of changes in neuronal function. Life Sciences, 1991, 48, 373-385.	4.3	44
243	Evidence for protein kinase C modulation of the ciliary muscle response to carbachol and desensitization. European Journal of Pharmacology, 1991, 204, 49-53.	3.5	7
244	Effect of a new cognition enhancer, alpha-glycerylphosphorylcholine, on scopolamine-induced amnesia and brain acetylcholine. Pharmacology Biochemistry and Behavior, 1991, 39, 835-840.	2.9	45
245	Modulation of rat skeletal muscle chloride channels by activators and inhibitors of protein kinase C. Pflugers Archiv European Journal of Physiology, 1991, 418, 500-503.	2.8	34
246	Calcium antagonists inhibit met-enkephalin immunoreactive material release: in vitro and ex vivo experiments. Journal of Neural Transmission, 1990, 80, 1-8.	2.8	8
247	Decrease in Phorbol Ester Receptors in Human Brain Tumors. European Neurology, 1990, 30, 241-246.	1.4	12
248	Regulation of phorbol ester binding and protein kinase C activity in aged rat brain. Neurobiology of Aging, 1990, 11, 563-566.	3.1	51
249	Chronic alcohol intake modifies phorbol ester binding in selected rat brain areas. Alcohol, 1989, 6, 169-172.	1.7	36
250	Direct coupling of a G-protein to dihydropyridine binding sites. Biochemical and Biophysical Research Communications, 1988, 156, 1279-1286.	2.1	27
251	Concomitant regulation of hippocampal calcium antagonist receptors and calcium uptake by Substance P. Biochemical and Biophysical Research Communications, 1987, 144, 1135-1142.	2.1	6
252	Erythrocyte 3H-ouabain binding and digitalis treatment in ethanol addicted patients. Life Sciences, 1987, 40, 2505-2509.	4.3	3

#	Article	IF	CITATIONS
253	Release of Met-enkephalin from rat striatal slices: effect of amphetamine and fipexide. Brain Research, 1986, 398, 212-214.	2.2	7
254	Neurotensin effect on dopamine release and calcium transport in rat striatum: interactions with diphenylalkylamine calcium antagonists. Naunyn-Schmiedeberg's Archives of Pharmacology, 1986, 332, 267-270.	3.0	43
255	Ranitidine and hypertension. Medical Journal of Australia, 1986, 144, 556-556.	1.7	2
256	Effect of Calcium Entry Blockade on ethanol-induced changes in bronchomotor tone. European Journal of Clinical Pharmacology, 1985, 28, 221-222.	1.9	5
257	Dopamine Uptake is Differentially Regulated in Rat Striatum and Nucleus Accumbens. Journal of Neurochemistry, 1985, 45, 51-56.	3.9	132
258	Neuronal control of brain microvessel function. Experientia, 1985, 41, 427-434.	1.2	66
259	Differential sensitivity of [3h]nitrendipine binding to cations of toxicological interest in various rat brain areas. Toxicology Letters, 1985, 27, 103-108.	0.8	4
260	Neuropeptides in human brain—postmortem studies. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1985, 9, 91-95.	4.8	28
261	Age-dependent increase in [3H]verapamil binding to rat cortical membranes. Neuroscience Letters, 1985, 61, 67-71.	2.1	35
262	Ethanol administration in vivo alters calcium ions control in rat striatum. Brain Research, 1985, 332, 376-379.	2.2	40
263	Age-related reduced affinity in [3H]nitrendipine labeling of brain voltage-dependent calcium channels. Brain Research, 1985, 333, 374-377.	2.2	62
264	Neurotensin effect on calcium transport and dopamine release in rat striatum. Regulatory Peptides, 1985, 10, 191-196.	1.9	0
265	Afferent fibers mediate the increase of met-enkephalin elicited in rat spinal cord by localized pain. Pain, 1984, 18, 25-31.	4.2	102
266	Chronic ethanol changes opiate receptor function in rat striatum. Brain Research, 1984, 293, 368-371.	2.2	22
267	Age related differences in dopamine-stimulated adenylate cyclase sensitivity to "in vivo―chronic ethanol treatment. Alcohol, 1984, 1, 263-267.	1.7	4
268	Changes of ?-Endorphin and Met-Enkephalin Content in the Hypothalamus-Pituitary Axis Induced by Aging. Journal of Neurochemistry, 1983, 40, 20-24.	3.9	72
269	In vivo characterization of the mechanisms that secrete enkephalin-like peptides stored in dog adrenal medulla. Neuropharmacology, 1981, 20, 639-645.	4.1	49
270	Impairment of brain neurotransmitter receptors in aged rats. Mechanisms of Ageing and Development, 1980, 12, 39-46.	4.6	85

#	Article	IF	CITATIONS
271	Secretion of enkephalin-like peptides from canine adrenal gland following splanchnic nerve stimulation. Neuropeptides, 1980, 1, 137-142.	2.2	64
272	Chronic lead treatment differentially affects dopamine synthesis in various rat brain areas. Toxicology, 1979, 12, 343-349.	4.2	68
273	[3H]haloperidol and [3H]spiroperidol receptor binding after striatal injection of kainic acid. Neuroscience Letters, 1978, 8, 207-210.	2.1	46
274	Dopamine receptor sensitivity in brain and retina of rats during aging. Brain Research, 1977, 138, 565-570.	2.2	121
275	Effect of desmethyldiazepam and chlordesmethyldiazepam on 3?,5?-cyclic guanosine monophosphate levels in rat cerebellum. Psychopharmacology, 1976, 50, 241-244.	3.1	9
276	Pharmacological Versus Non-Pharmacological and Ancillary Mechanisms in Eye Drops Used in the Treatment of Glaucoma. Frontiers in Drug Safety and Regulation, 0, 2, .	1.8	1